Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 following chronic dosing (7 Days) in Patients with Moderate to Very Severe chronic obstructive pulmonary disease (COPD)

Trial Identifier: PT0031002
Sponsor: Pearl Therapeutics, Inc.
NCTID:: NCT01085045
Start Date: March 2010
Primary Completion Date: November 2010
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia, NSW Caringbah, NSW, Australia, 2229
Australia, NSW Glebe, NSW, Australia, 2037
Australia, NSW Hornsby, NSW, Australia, 2077
Australia, Qld Auchenflower, Qld, Australia, 4066
Australia, Qld Herston, Qld, Australia, 4006
Australia, South Australia Adelaide, South Australia, Australia
Australia, Vic Clayton, Vic, Australia, 3168
Australia, WA Nedlands, WA, Australia, 6006
New Zealand, Auckland Epsom, Auckland, New Zealand, 1051
New Zealand, Auckland Greenlane East, Auckland, New Zealand, 1051
New Zealand, Waikato Hamilton, Waikato, New Zealand, 3240
New Zealand, Wellington Crofton Downs, Wellington, New Zealand, 6143
USA, FL Clearwater, FL, USA, 33765
USA, NC Charlotte, NC, USA, 28207
USA, OR Medford, OR, USA, 97504
USA, South Carolina Spartanburg, South Carolina, USA, 29303